Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.54
EXEL's Cash to Debt is ranked higher than
52% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. EXEL: 0.54 )
EXEL' s 10-Year Cash to Debt Range
Min: 0.54   Max: No Debt
Current: 0.54

Equity to Asset -0.15
EXEL's Equity to Asset is ranked higher than
52% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. EXEL: -0.15 )
EXEL' s 10-Year Equity to Asset Range
Min: -0.7   Max: 0.8
Current: -0.15

-0.7
0.8
F-Score: 1
Z-Score: -7.69
M-Score: -3.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1075.61
EXEL's Operating margin (%) is ranked higher than
58% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. EXEL: -1075.61 )
EXEL' s 10-Year Operating margin (%) Range
Min: -673.24   Max: 30.91
Current: -1075.61

-673.24
30.91
Net-margin (%) -1272.72
EXEL's Net-margin (%) is ranked higher than
56% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. EXEL: -1272.72 )
EXEL' s 10-Year Net-margin (%) Range
Min: -781.03   Max: 26.14
Current: -1272.72

-781.03
26.14
ROE (%) -653.61
EXEL's ROE (%) is ranked lower than
51% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. EXEL: -653.61 )
EXEL' s 10-Year ROE (%) Range
Min: -2156.15   Max: -35.6
Current: -653.61

-2156.15
-35.6
ROA (%) -59.08
EXEL's ROA (%) is ranked higher than
61% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. EXEL: -59.08 )
EXEL' s 10-Year ROA (%) Range
Min: -134.14   Max: 20.08
Current: -59.08

-134.14
20.08
ROC (Joel Greenblatt) (%) -5380.49
EXEL's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. EXEL: -5380.49 )
EXEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3659.99   Max: 736.4
Current: -5380.49

-3659.99
736.4
Revenue Growth (3Y)(%) -53.70
EXEL's Revenue Growth (3Y)(%) is ranked higher than
59% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. EXEL: -53.70 )
EXEL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -53.7   Max: 25.6
Current: -53.7

-53.7
25.6
EBITDA Growth (3Y)(%) 16.90
EXEL's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. EXEL: 16.90 )
EXEL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -44.8   Max: 17.8
Current: 16.9

-44.8
17.8
EPS Growth (3Y)(%) 16.10
EXEL's EPS Growth (3Y)(%) is ranked higher than
88% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. EXEL: 16.10 )
EXEL' s 10-Year EPS Growth (3Y)(%) Range
Min: -42.1   Max: 16.1
Current: 16.1

-42.1
16.1
» EXEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

EXEL Guru Trades in Q4 2013

Steven Cohen 14,300 sh (New)
Jean-Marie Eveillard 1,173,300 sh (unchged)
» More
Q1 2014

EXEL Guru Trades in Q1 2014

Paul Tudor Jones 15,713 sh (New)
Louis Moore Bacon 250,000 sh (New)
Steven Cohen 17,977 sh (+25.71%)
Jean-Marie Eveillard 400,000 sh (-65.91%)
» More
Q2 2014

EXEL Guru Trades in Q2 2014

Jim Simons 1,658,150 sh (New)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Jean-Marie Eveillard Sold Out
» More
Q3 2014

EXEL Guru Trades in Q3 2014

Paul Tudor Jones 28,200 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 Sold Out $3.22 - $3.8 $ 1.33-61%0
Jean-Marie Eveillard 2014-03-31 Reduce -65.91%0.01%$3.38 - $8.24 $ 1.33-81%400000
John Burbank 2013-03-31 Sold Out 0.0019%$4.41 - $5.03 $ 1.33-72%0
John Burbank 2012-12-31 New Buy$4.33 - $5.32 $ 1.33-72%10753
Jean-Marie Eveillard 2012-09-30 Add 422.58%0.02%$4.28 - $6.45 $ 1.33-75%1175800
Jean-Marie Eveillard 2012-03-31 Add 125%$4.49 - $6.47 $ 1.33-74%225000
Jean-Marie Eveillard 2011-12-31 New Buy$3.95 - $7.81 $ 1.33-74%100000
Carl Icahn 2011-09-30 Sold Out 0.43%$5.5 - $9.22 $ 1.33-82%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 12.09
EXEL's P/S is ranked higher than
80% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. EXEL: 12.09 )
EXEL' s 10-Year P/S Range
Min: 1.65   Max: 50.5
Current: 12.09

1.65
50.5
EV-to-EBIT -1.78
EXEL's EV-to-EBIT is ranked higher than
70% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EXEL: -1.78 )
EXEL' s 10-Year EV-to-EBIT Range
Min: -26.8   Max: 41.3
Current: -1.78

-26.8
41.3
Current Ratio 1.27
EXEL's Current Ratio is ranked higher than
54% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. EXEL: 1.27 )
EXEL' s 10-Year Current Ratio Range
Min: 0.84   Max: 9.35
Current: 1.27

0.84
9.35
Quick Ratio 1.25
EXEL's Quick Ratio is ranked higher than
56% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. EXEL: 1.25 )
EXEL' s 10-Year Quick Ratio Range
Min: 0.84   Max: 9.35
Current: 1.25

0.84
9.35

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.51
EXEL's Price/Median PS Value is ranked higher than
78% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. EXEL: 1.51 )
EXEL' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 4.79
Current: 1.51

0.25
4.79
Earnings Yield (Greenblatt) -56.20
EXEL's Earnings Yield (Greenblatt) is ranked higher than
51% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. EXEL: -56.20 )
EXEL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.4   Max: 16.4
Current: -56.2

2.4
16.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EX9.Germany,
Exelixis Inc incorporated in November, 1994. It is a biotechnology company which develops small molecule therapies to treat cancer. Its two advanced assets, COMETRIQ "cabozantinib", its wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib "GDC-0973/XL518", a potent, highly selective inhibitor of MEK, which it out-licensed to Genentech, Inc. a wholly-owned member of the Roche Group, or Genentech, are currently the subject of six ongoing phase 3 pivotal trials. Cabozantinib is being evaluated in a development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer or CRPC, an ongoing phase 3 pivotal trial in metastatic renal cell cancer or RCC, and an ongoing phase 3 pivotal trial in advanced hepatocellular cancer, or HCC. The programs that the Company runs are Cabozantinib Development Program, CRPC, COMET Pivotal Trials, Combination trials. The Company has development programs in collaboration with Genentech, GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited. It contracts third parties to manufacture raw materials, the active pharmaceutical ingredient, or API, and finished solid dose COMETRIQ products for clinical and commercial uses. The Company follows regulations set forth by FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries. Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, are applicable to the Company.
» More Articles for EXEL

Headlines

Articles On GuruFocus.com
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs Dec 12 2008 

More From Our Partners
Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog Dec 16 2014 - ZACKS

More From Other Websites
Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and... Dec 15 2014
Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and... Dec 15 2014
EXELIXIS, INC. Files SEC form 8-K, Other Events Dec 05 2014
Exelixis Shares Down on COMET-2 Study Results on Cabozantinib Dec 02 2014
Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study Dec 01 2014
Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With... Dec 01 2014
Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With... Dec 01 2014
Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 Nov 25 2014
Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 Nov 25 2014
Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888... Nov 16 2014
EXELIXIS, INC. Financials Nov 14 2014
Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 Nov 11 2014
Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 Nov 11 2014
Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic... Nov 06 2014
Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic... Nov 06 2014
Exelixis tops 3Q profit forecasts Nov 04 2014
Exelixis tops 3Q profit forecasts Nov 04 2014
Exelixis Inc Earnings Call scheduled for 5:00 pm ET today Nov 04 2014
Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update Nov 04 2014
Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in... Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK